GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
GenScript Biotech Corporation signs exclusive agreement with PH biotech firm to distribute faster, more accurate and more affordable immunity tests for COVID-19
SINGAPORE, Sept. 1, 2020 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) entered an exclusive partnership with Philippines biotech company, IP Biotech. ). This will allow the firm to distribute a breakthrough test kit designed to measure the levels of neutralizing...
GenScript Reports 2020 Interim Results and Provides Business Update
NANJING, China, Aug. 31, 2020 /PRNewswire/ -- GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, today reported interim results for the six months endedJune 30, 2020 and provided a corporate update. Revenue of the Group for the six months endedJune 30, 2020 was...
Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen
* As a first-in-the-world "rapid smart test kit", the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficacy...
Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen
* As a first-in-the-world "rapid smart test kit", the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficac...
GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs
NANJING, China and SEOUL, South Korea, April 7, 2020 /PRNewswire/ -- GenScript Biotech Corporation's CDMO business GenScript ProBio (hereinafter referred to as GenScript ProBio) and Eutilex Co., Ltd. (hereinafter referred to as Eutilex) committed to developing anti-cancer immunotherapy technology...
GenScript Biotech Reports 2019 Financial Results and Provides Business Update
NANJING, China, April 1, 2020 /PRNewswire/ -- GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, yesterday reported full year 2019 financial results and provided a corporate update. In 2019, overall revenue of the Group was approximatelyUS$273.4 million, repres...
GenScript and Selecxine Enter Into Strategic Cooperation Agreement
SEOUL, South Korea, Dec. 26, 2019 /PRNewswire/ -- On Dec. 23, 2019, at Seoul, South Korea, the CDMO segment of the world's leading biotech company GenScript announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics f...
China's Largest Plasmid and Virus Facility from GenScript was Put into Operation
ZHENJIANG, China, Dec. 20, 2019 /PRNewswire/ -- The CDMO segment of the world's leading biotech company GenScript announced that GenScript's plasmid and virus facility was put into operation onDecember 18, 2019. It is a milestone on the path to industrialization of the gene and cell therapy indus...
